BLU
Price:
$14.745
Market Cap:
$1.87B
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.[Read more]
Industry
Biotechnology
IPO Date
2000-10-27
Stock Exchange
NASDAQ
Ticker
BLU
According to BELLUS Health Inc.’s latest financial reports and current stock price. The company's current ROE is -13.91%. This represents a change of 227.99% compared to the average of -4.24% of the last 4 quarters.
The mean historical ROE of BELLUS Health Inc. over the last ten years is -17.47%. The current -13.91% ROE has changed -20.38% with respect to the historical average. Over the past ten years (40 quarters), BLU's ROE was at its highest in in the December 2015 quarter at 9.81%. The ROE was at its lowest in in the September 2021 quarter at -23.95%.
Average
-17.47%
Median
-20.54%
Minimum
-29.93%
Maximum
2.23%
Discovering the peaks and valleys of BELLUS Health Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 155.65%
Maximum Annual ROE = 2.23%
Minimum Annual Increase = -1269.45%
Minimum Annual ROE = -29.93%
Year | ROE | Change |
---|---|---|
2022 | -19.46% | -20.22% |
2021 | -24.39% | 12.85% |
2020 | -21.61% | -27.78% |
2019 | -29.93% | 83.33% |
2018 | -16.32% | 128.98% |
2017 | -7.13% | -72.72% |
2016 | -26.13% | -1269.45% |
2015 | 2.23% | -109.72% |
2014 | -22.99% | 155.65% |
2013 | -8.99% | -93.31% |
The current ROE of BELLUS Health Inc. (BLU) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-21.82%
5-year avg
-22.34%
10-year avg
-17.47%
BELLUS Health Inc.’s ROE is greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Inozyme Pharma, Inc. (-68.93%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than KalVista Pharmaceuticals, Inc. (-97.37%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Kura Oncology, Inc. (-40.43%), greater than Viridian Therapeutics, Inc. (-49.65%), less than Biomea Fusion, Inc. (0%), greater than Stoke Therapeutics, Inc. (-91.86%), greater than Akero Therapeutics, Inc. (-57.89%), greater than Homology Medicines, Inc. (-29.56%), greater than Gossamer Bio, Inc. (-100.91%), greater than Cytokinetics, Incorporated (-117.33%), less than DICE Therapeutics, Inc. (196.01%), greater than Edgewise Therapeutics, Inc. (-102.37%), greater than Karuna Therapeutics, Inc. (-28.01%), greater than Dyne Therapeutics, Inc. (-30.79%), greater than null (-68.85%),
Company | ROE | Market cap |
---|---|---|
-39.58% | $549.60M | |
-46.15% | $161.36M | |
-24.63% | $133.38M | |
-68.93% | $312.42M | |
32.93% | $109.78M | |
-97.37% | $531.63M | |
-62.63% | $4.03B | |
-24.51% | $181.50M | |
-40.43% | $1.48B | |
-49.65% | $900.21M | |
0% | $256.37M | |
-91.86% | $773.92M | |
-57.89% | $1.83B | |
-29.56% | $3.02M | |
-100.91% | $205.87M | |
-117.33% | $6.36B | |
196.01% | $2.27B | |
-102.37% | $1.64B | |
-28.01% | $12.60B | |
-30.79% | $3.32B | |
-68.85% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BELLUS Health Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BELLUS Health Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is BELLUS Health Inc.'s ROE?
How is the ROE calculated for BELLUS Health Inc. (BLU)?
What is the highest ROE for BELLUS Health Inc. (BLU)?
What is the 3-year average ROE for BELLUS Health Inc. (BLU)?
What is the 5-year average ROE for BELLUS Health Inc. (BLU)?
How does the current ROE for BELLUS Health Inc. (BLU) compare to its historical average?